Yazar "Yalcinsoy, M." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Inhaled nitric oxide as rescue therapy in severe ARDS cases due to COVID-19 pneumonia: a single center experience
    (Verduci Publisher, 2023) Bicakcioglu, M.; Kalkan, S.; Duzenci, D.; Yalcinsoy, M.; Dogan, Z.; Ozer, A. B.
    OBJECTIVE: Inhaled NO (iNO) has been recommended as rescue therapy in acute respiratory stress syndrome (ARDS) cas-es. In this study, we aimed to demonstrate the efficacy of iNO as a rescue therapy in patients with severe ARDS due to COVID-19.PATIENTS AND METHODS: This retrospec-tive study included patients with ARDS due to COVID-19 who were treated with iNO between March 2020 and January 2022 in the intensive care unit (ICU) of Inonu University. Patients' files were reviewed retrospectively, and de-mographic data, APACHE II and Sequential Or-gan Failure Assessment (SOFA) scores, initia-tion day of iNO and duration of iNO treatment, length of stay in hospital/ICU, blood biochem-istry values, complete blood counts, inflamma-tory parameters, arterial blood gas values, lac-tate, PaO2/FiO2 ratios, anti-inflammatory drugs and outcome were recorded.RESULTS: Data from 16 patients were reached. iNO was given at a dose of 20 ppm continuously. The mean duration of treatment with iNO was 3.5 days. All patients took the prone position except a single patient. While all patients received steroid therapy, four pa-tients received anti-cytokine therapy, and five patients received intravenous immunoglobulin therapy. All patients were in severe ARDS with a mean PaO2/FiO2 ratio of 58 before iNO ther-apy. A significant increase in PaO2/FiO2 val-ues was detected with the use of iNO (p<0.05). While three patients (19%) were discharged from the ICU, thirteen patients died.CONCLUSIONS: In our study, it was deter-mined that iNO applied as a rescue treatment in patients with severe ARDS improved oxygen-ation. Although the effect of iNO on survival was low, it may be interpreted as clinically signifi-cant considering the severity of the general clin-ical condition of the patients.
  • Küçük Resim Yok
    Öğe
    Prognosis of hospitalized patients with community-acquired pneumonia
    (Elsevier Science Bv, 2018) Akyil, F. Tokgoz; Yalcinsoy, M.; Hazar, A.; Cilli, A.; Celenk, B.; Kilic, O.; Sayiner, A.
    Introduction: The long-term prognosis of patients with community-acquired pneumonia (CAP) has attracted increasing interest in recent years. The objective of the present study is to investigate the short and long-term outcomes in hospitalized patients with CAP and to identify the predictive factors associated with mortality. Patients and methods: The study was designed as a retrospective, multicenter, observational study. Hospitalized patients with CAP, as recorded in the pneumonia database of the Turkish Thoracic Society between 2011 and 2013, were included. Short-term mortality was defined as 30-day mortality and long-term mortality was assessed from those who survived 30 days. Predictive factors for short- and long-term mortality were analyzed. Results: The study included 785 patients, 68% of whom were male and the mean age was 67 +/- 16 (18-92). The median duration of follow-up was 61.2 +/- 11.8 (37-90) months. Thirty-day mortality was 9.2% and the median survival of patients surviving 30 days was 62.8 +/- 4.4 months. Multivariate analysis revealed that advanced age, the absence of fever, a higher Charlson comorbidity score, higher blood urea nitrogen (BUN)/albumin ratios and lower alanine aminotransferase (ALT) levels were all predictors of long-term mortality. Conclusion: Long-term mortality following hospitalization for CAP is high. Charlson score and lack of fever are potential indicators for decreased long-term survival. As novel parameters, baseline BUN/albumin ratios and ALT levels are significantly associated with late mortality. Further interventions and closer monitoring are necessary for such subgroups of patients. (C) 2017 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L.U.